drugset
Drugs / Newly matched donor-derived CD5 CAR T-cells
last change Jul 2025 re-read 3 minutes ago

Newly matched donor-derived CD5 CAR T-cells

Cell therapy targets CD5

Developed for
T-cell acute lymphoblastic leukemia · T-cell and NK-cell neoplasm
Investigated by
Beijing GoBroad Hospital · Central People's Hospital of Zhanjiang · First Affiliated Hospital of Guangxi Medical University · Shanghai Liquan Hospital · The General Hospital of Western Theater Command · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

Trials 1

today NCT07070323 · Ph 1/2
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07070323 Jul 2025 → Dec 2026 expected T-cell acute lymphoblastic leukemia, T-cell and NK-cell neoplasm Beijing GoBroad Hospital Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Newly matched donor-derived CD5 CAR T-cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT07070323 ↗
Modality Cell therapy “anti-CD5 CAR-T cell therapy” NCT07070323 ↗
Route Other “receive newly matched donor-derived CD5 CAR T-cell infusion” NCT07070323 ↗
Target CD5 “anti-CD5 CAR-T cell therapy” NCT07070323 ↗